Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers.
Axol Bioscience has raised $2.8M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in January 2026.
Axol Bioscience's investors include Amadeus Capital Partners, SyndicateRoom, BroadOak Capital Partners, Par Equity, Scottish Enterprise.
Axol Bioscience is headquartered in Cambridge, United States.
Axol Bioscience sells live human cell cultures and provides services such as genome editing to researchers.
Axol Bioscience is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Axol Bioscience — Funding & Investors." VCBacked, January 13, 2026, https://www.vcbacked.co/company/axol-bioscience. Accessed September 29, 2026.
VCBacked. (2026). Axol Bioscience — Funding & Investors. Retrieved September 29, 2026, from https://www.vcbacked.co/company/axol-bioscience
{{cite web |title=Axol Bioscience — Funding & Investors |url=https://www.vcbacked.co/company/axol-bioscience |website=VCBacked |access-date=September 29, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated